chemotherapeutic agent


Also found in: Dictionary, Thesaurus, Legal, Financial, Encyclopedia.
Related to chemotherapeutic agent: chemotherapy

chemotherapeutic agent

[-ther′əpyo̅o̅′tik]
any chemical used to treat cancer. It is usually used to refer to antineoplastic drugs.

chemotherapeutic agent

An agent used to treat cancer administered in regimens of one or more cycles, combining two or more agents over a period of days to weeks. Such agents are toxic to cells with high proliferative rates—e.g., to the cancer itself, but also to the GI tract (causing nausea and vomiting), bone marrow (causing various cytopenias) and hair (resulting in baldness).

Examples
Busulphan, cisplatin, cyclophosphamide, MTX, daunorubicin, doxorubicin, melphalan, vincristine, vinblastine, chlorambucil.

chemotherapeutic agent

An agent used to treat CA, administered in 'regimens'-one or more 'cycles' that combine 3 or more agents over wks; CAs are toxic to any cell with a high rate of proliferation–the CA itself, the GI tract–causing N&V, BM–cytopenias, and hair—alopecia Examples Busulphan, cisplatin, cyclophosphamide, MTX, daunorubicin, doxorubicin, melphalan, vincristine, vinblastine, chlorambucil. See Immunosuppressive agents.

che·mo·ther·a·peu·tic a·gent

(kēmō-thār-ă-pyūtik ājĕnt)
Chemical that is used for therapeutic reasons.
References in periodicals archive ?
1) The cells overexpressing P-gp pumps indeed manage to survive the initial chemotherapy, possibly to form a new clonal population of cancer cells, from now on refractory to most chemotherapeutic agents (See Figure 3).
Local chemotherapeutic agents offer an additional mode of therapy and should be used on a case-to-case basis, not necessarily as an initial treatment.
Researchers from the National Cancer Institute and six cancer hospitals in the United States and Italy report that the risk of bone cancer among survivors of a variety of childhood cancers rises sharply with increasing exposure to radiation or certain chemotherapeutic agents, reaching 40-fold at some of the highest doses used.
The APF530 Phase 3 pivotal trial protocol includes a total of approximately 1,350 patients, about half of which will receive moderately emetogenic chemotherapeutic agents with the other half receiving highly emetogenic chemotherapeutic agents.
In January 2006, Endocyte also entered into a licensing agreement with Bristol-Myers Squibb for the development of targeted epothilone-based chemotherapeutic agents.
AmpliMed's multi-center studies using a combination of Amplimexon[R] and common chemotherapeutic agents in Stage IV metastatic melanoma (Phase II) and advanced pancreatic adenocarcinoma (Phase Ib) are scheduled to be completed early next year.
This is an important distinction between ONCONASE over other standard chemotherapeutic agents (DNA damaging agents).